Chad Kolean New CFO at Titan Spine
Elizabeth Hofheinz, M.P.H., M.Ed. • Thu, October 5th, 2017
Chad Kolean, a 25-year veteran of the bioscience industry, is the new Chief Financial Officer (CFO) of Mequon-Wisconsin-based Titan Spine, LLC.
As the company wrote in its September 12, 2017 news release, “Prior to joining Titan, Mr. Kolean served as the CFO for Cellectar Biosciences, a life sciences company, where he drove a management restructuring and raised substantial funds resulting in up listing to the NASDAQ Capital Market. Previously, he served as the CFO at Pioneer Surgical Technologies, providing the organization with leadership strategy, development and execution, Board support, investor relations, budgeting, forecasting, operations and regulatory due diligence. Kolean is a certified public accountant and earned his B.A. in Business Administration from Hope College.”
Kolean commented, “I am thrilled to join the team at Titan Spine, particularly at such an exciting time for the company. We are well-positioned for continued financial growth that capitalizes on a strong first half of 2017. Titan Spine is making substantial progress addressing the key needs for both patients and surgeons, and the company’s growth is a direct reflection of the increased demand surgeons have for the advantages of our nanoLOCK surface technology.”
Peter Ullrich, Chief Executive Officer of Titan Spine, added, “Chad’s appointment as our CFO validates and reflects our rapid expansion as we continue to disrupt our industry and redefine the role of interbody devices in the fusion process. The growing demand for our technology and our strong sales team has led to significant growth, especially in the first half of this year, and we believe Chad will help drive our continued progress, further benefiting patients at the nano-cellular level to heal faster following spinal fusions.”
Kolean told OTW, “My initial goal is to assess how the company can optimize its operations from a financial perspective and ensure that we are focused on using our resources to most effectively drive the attainment of our near and long-term objectives. Titan has done an excellent job of generating market-leading sales growth to date due, in large part, to the company’s commitment to improving patient outcomes. The burgeoning demand for our nanoLOCK surface technology creates a unique opportunity for our talented finance team, and we look forward to supporting the rest of the organization during this time of hypergrowth moving forward.”